Medicare AdvantageJune 29, 2023
Clinical Criteria updates - March 2023
On August 19, 2022, and March 23, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised |
August 6, 2023 | *CC-0235 | Revcovi (elapegademase-lvlr) | New |
August 6, 2023 | *CC-0236 | Signifor LAR (pasireotide) | New |
August 6, 2023 | CC-0125 | Opdivo (nivolumab) | Revised |
August 6, 2023 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
August 6, 2023 | CC-0038 | Human Parathyroid Hormone Agents | Revised |
August 6, 2023 | CC-0066 | Monoclonal Antibodies to Interleukin-6 | Revised |
August 6, 2023 | *CC-0197 | Jemperli (dostarlimab-gxly) | Revised |
August 6, 2023 | *CC-0119 | Yervoy (ipilimumab) | Revised |
August 6, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised |
August 6, 2023 | *CC-0065 | Hemophilia A and von Willebrand Disease | Revised |
August 6, 2023 | *CC-0034 | Agents for Hereditary Angioedema | Revised |
August 6, 2023 | CC-0061 | GnRH Analogs for the Treatment of Non-Oncologic Indications | Revised |
August 6, 2023 | CC-0008 | Subcutaneous Hormonal Implants | Revised |
August 6, 2023 | CC-0026 | Testosterone, Injectable | Revised |
MULTI-BCBS-CR-027354-23-CPN26411
PUBLICATIONS: August 2023 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/georgia/articles/clinical-criteria-updates-for-march-2023-1-14226
Or scan this QR code with your phone